]>
IRCT20101107005123N3 IRCT 2023-02-18 Mashhad University of Medical Sciences Effect of silymarin in inflammatory bowel disease Evaluation of the effect of silymarin in patients with inflammatory bowel disease 2023-04-21 anticipated 40 Complete https://irct.ir/trial/68422 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly divided into two groups receiving silymarin tablets and placebo. Random numbers table is used for randomization. In order to use random numbers table, it will be determined first to read the numbers in the table, then the numbers are considered for different groups. We put our hands on one of the numbers and move in one of the predetermined directions and assign the numbers to the desired groups, Blinding description: Patients in the intervention group will use silymarin tablets and the control group will use placebo, similar to the intervention group. Patients and doctors who evaluate the outcome will be unaware of the type of drug received. 3 Inflammatory Bowel Disease. Intervention 1: Intervention group: Silymarin tablets (Gol Daro Company) with a dose of 5 mg/kg in divided doses three times a day for three months on a daily basis. Intervention 2: Control group: Three times a day placebo for three months on a daily basis. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is The results are not yet known
public Mashhad University of Medical Sciences
Akbar Hospital, Kaveh Blvd, Mashhad
Mashhad Iran (Islamic Republic of) ٩١٧٧٨٩٧١۵٧ +98 51 3871 3801 fatemehamaanii@gmail.com Mashhad University of Medical Sciences scientific Fatemeh Amani
Akbar Hospital, Kaveh Blvd, Mashhad
Mashhad Iran (Islamic Republic of) ٩١٧٧٨٩٧١۵٧ +98 51 3871 3801 fatemehamaanii@gmail.com Mashhad University of Medical Sciences Iran (Islamic Republic of) Inflammatory bowel disease 5 years 18 years Both The patient's unwillingness to visit the gastroenterology clinic regularly for regular examinations and check-ups Presence of any other comorbidities K50-K52 Noninfective inflammatory bowel disease Treatment - Drugs Treatment - Drugs Intervention group: Silymarin tablets (Gol Daro Company) with a dose of 5 mg/kg in divided doses three times a day for three months on a daily basis Control group: Three times a day placebo for three months on a daily basis Clinical Symptoms. Timepoint: Before the start of the study, one month and three months after the start of the intervention. Method of measurement: Questionnaire including abdominal pain, frequency of defecation, mobility and endoscopy findings. Mashhad University of Medical Sciences Approved 2022-11-15 Ethics committee of Mashhad University of Medical Sciences Vice chancellor for research, Mashhad University of Medical Sciences, Daneshgah Ave, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)